The third dose of Corona Pfizer vaccine will soon be approved by the FDA

دوز سوم واکسن کرونا فایزر به زودی از FDA مجوز دریافت می‌کند

The US Food and Drug Administration (FDA) is likely to approve a booster dose of the Corona Pfizer vaccine for all adults soon. On this account, if approved by regulators, all adults who received the second dose of the vaccine at least six months ago will be eligible for the third dose of the vaccine.

The Centers for Disease Control and Prevention (CDC) and the Vaccine Advisory Committee should develop a booster dose program before it is available to the general public. To confirm. According to the New York Times, the committee will hold a meeting on Friday, but the Centers for Disease Control and Prevention has not yet issued a statement on the report.

The Food and Drug Administration last month approved a third dose of the Corona Pfizer vaccine for high-risk adults 65 years of age and older. Also last month, the Food and Drug Administration approved a third dose of the modern vaccine for at-risk adults 65 years of age or older, as well as a third dose of the Johnson & Johnson vaccine for adults at least 18 years old.

In addition, the FDA last month provided another option for eligible individuals to use other vaccines when receiving a third dose. Despite this rule, a person who has received his or her initial dose from one type of vaccine can receive his or her third dose from another company’s vaccine.

Last week, Pfizer asked the FDA to approve its booster dose for all adults over the age of 18. The results of various studies show that the effectiveness of the vaccine can be reduced after six to eight months. Recent scientific studies have also shown that the Pfizer booster dose is 95.6% effective against the corona virus.

While boosting doses can provide greater protection for millions, only about 4.6 percent of people in low-income countries have received at least one dose of the Corona vaccine.

More Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.
You need to agree with the terms to proceed

Most Viewed Posts